Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
BRISBANE, Calif., May 07, 2018 -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX) today announced the closing of the Company’s initial public offering of 5,000,000 shares of common stock at a public offering price of $17.00 per share, which does not include the exercise by the underwriters of their option to purchase up to an additional 750,000 shares of common stock. Aggregate gross proceeds to the Company were approximately $85.0 million, before underwriting discounts, commissions and estimated offering expenses. All of the shares in the offering were offered by UNITY. UNITY’s common stock is listed on The Nasdaq Global Select Market under the ticker symbol “UBX.”
Goldman Sachs & Co. LLC, Morgan Stanley and Citigroup acted as joint book-running managers for the offering. Mizuho Securities acted as a lead manager for the offering.
A registration statement relating to the shares sold in this offering was declared effective by the Securities and Exchange Commission on May 2, 2018. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from (1) Goldman Sachs & Co. LLC., Attention: Prospectus Department, 200 West Street, New York, NY 10282, Telephone: 1-866-471-2526; (2) Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; and (3) Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 1-800-831-9146.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About UNITY Biotechnology, Inc.
UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related afflictions, such as osteoarthritis, eye diseases and pulmonary diseases. UNITY's seasoned management team has experience building companies and developing medicines.
Contact: Investors Bob Goeltz [email protected] 1-650-525-4980 Media Canale Communications Jason Spark [email protected] 1-619-849-6005
